account_balance
Investment manager · 13F filer · SEC CIK 1703031
Bain Capital Life Sciences Investors, LLC
Reported value$1.68Bas of Jun 30, 2026
Positions21 2 new, 1 sold out
Top 10 weight87.9%KLRA alone is 30%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
KLRAKailera Therapeutics Inc
29.6%New
HTFLHeartflow Inc
14.7%Trimmed −19%
NAMSNewamsterdam Pharma Company
7.7%Trimmed −48%
SVRASavara Inc
6.4%
ALKSAlkermes PLC
6.0%Added +218%
SLDBSolid Biosciences Inc
5.8%
PHVSPharvaris N V
5.5%
OLMAOlema Pharmaceuticals Inc
5.3%Trimmed −5%
COAG3.6%CABACabaletta Bio Inc
3.2%Added +78%
XFORX4 Pharmaceuticals Inc
2.2%
DNTHDianthus Therapeutics Inc
2.1%
KLRAKailera Therapeutics Inc
29.6%New
HTFL14.7%NAMS7.7%SVRA6.4%ALKS6.0%SLDB5.8%PHVS5.5%OLMA5.3%COAG3.6%CABA3.2%XFOR2.2%DNTH2.1%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
KLRA Kailera Therapeutics Inc 29.6% NewHTFL Heartflow Inc 14.7% Trimmed −19%NAMS Newamsterdam Pharma Company 7.7% Trimmed −48%SVRA Savara Inc 6.4% HeldALKS Alkermes PLC 6.0% Added +218%SLDB Solid Biosciences Inc 5.8% HeldPHVS Pharvaris N V 5.5% HeldOLMA Olema Pharmaceuticals Inc 5.3% Trimmed −5%COAG Hemab Therapeutics Holdings Inc 3.6% NewCABA Cabaletta Bio Inc 3.2% Added +78%XFOR X4 Pharmaceuticals Inc 2.2% HeldDNTH Dianthus Therapeutics Inc 2.1% Held
What changed